Research Bcell
Related Resources for this page:
- Future Directions
- Antibody-Drug Conjugates
- A brief history of ADCs
- Current research in ADCs
- Cytotoxic agent
- Emerging therapeutic options
- Emerging therapeutic options
- HER Signaling
- How are ADCs designed to work?
- Glossary
- Monoclonal antibody
- Research ADCs
- Slide decks and videos
- Stable linker
- Targeting cancers with ADCs
- Trastuzumab Emtansine (T-DM1)
- What are ADCs?
- Antibody-Drug conjugates
- Apoptosis
- Bispecific Monoclonal Antibodies
- Glycoengineered Antibodies
- Non-Antibody Biologics
- Targeted Small Molecules
- Apoptosis
- Apoptotic pathways
- The Bcl-2 family
- Apoptosis
- Emerging therapeutic options
- Emerging therapeutic options
- Resisting apoptosis
- Gastric Cancer
- HER1/EGFR as a therapeutic target
- MAPK Signaling
- MEK Inhibitor (GDC-0973)
- Melanoma
- Emerging therapeutic options
- PI3K Inhibitor (GDC-0941)
- Reactivating apoptosis
- PI3K/Akt/mTOR Signaling
- Therapeutic potential of HER pathways
- Slide decks and videos
- What are the strategies for inhibiting the VEGF pathway?
- Traditional Monoclonal Antibodies
- Anti-EGFL7
- B-cell Surface Proteins
- Glossary
- Direct cell death
- Emerging therapeutic options
- Emerging therapeutic options
- The evolving CLL treatment landscape
- Gastric Cancer
- HER Signaling
- HER1/EGFR as a therapeutic target
- HER2:HER3 dimer
- HER2 as a therapeutic target
- HER3 as a therapeutic target
- Melanoma
- Emerging therapeutic options
- Obinutuzumab (GA101)
- Angiogenic Signaling
- Inhibition of HER2 dimerization
- Therapeutic potential of HER pathways
- Slide decks and videos
- What are the strategies for inhibiting the VEGF pathway?
- Antibody-Drug Conjugates
Share
Cellular characteristics associated with the development of cancer cells
- When a cell undergoes malignant transformation, it goes through important cellular changes. These hallmarks of cancer are shown in Figure 1
- The hallmarks of cancer that are most relevant to hematology include evading apoptosis, self-sufficiency of growth signals, and insensitivity to antigrowth signals

This figure was adapted with permission from Cell, Vol 100, Hanahan and Weinberg, The Hallmarks of Cancer, pp 57-70, Copyright Elsevier (2000)1.